Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients

NeuroMolecular Medicine

Volumn 14, Issue 1, 2012, Pages 84-90

  Gorgone, Gaetano ^a   Currò, Monica ^b   Ferlazzo, Nadia ^b   Parisi, Giulia ^b   Parnetti, Lucilla ^e   Belcastro, Vincenzo ^d   Tambasco, Nicola ^e   Rossi, Aroldo ^e   Pisani, Francesco ^c   Calabresi, Paolo ^e,f   Ientile, Riccardo ^b   Caccamo, Daniela ^b  

^a IRCCS Neurolesi Bonino Pulejo   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d SANT ANNA HOSPITAL   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Coenzyme Q10; Homocysteine; Levodopa; MTHFR polymorphisms; Parkinson's disease

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; CYTIDINE; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; THYMIDINE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENZYME ASSAY; FEMALE; FOLIC ACID BLOOD LEVEL; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; MUTATOR GENE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; VITAMIN BLOOD LEVEL;

AGED; ANTIPARKINSON AGENTS; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LEVODOPA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC; UBIQUINONE; VITAMIN B 12;

EID: 84858001526     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-012-8174-1     Document Type: Article

References (39)

1. Beal, M. F. (2003). Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Annals of the New York Academy of Science, 991, 120-131.
2. Caccamo, D., Condello, S., Gorgone, G., Crisafulli, G., Belcastro, V., Gennaro, S., et al. (2004). Screening for C677T and A1298C MTHFR polymorphisms in patients with epilepsy and risk of hyperhomocysteinemia. Neuromolecular Medicine, 6, 117-126. (Pubitemid 41265781)
3. Caccamo, D., Gorgone, G., Currò, M., Parisi, G., Di Iorio, W., Menichetti, C., et al. (2007). Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated parkinsonian patients. Neuromolecular Medicine, 9, 249-254. (Pubitemid 350129699)
4. Cartelli, D., Ronchi, C., Maggioni, M. G., Rodighiero, S., Giavini, E., & Cappelletti, G. (2010). Microtubule dysfunction precedes transport impairment and mitochondria damage in MPP+-induced neurodegeneration. Journal of Neurochemistry, 115(1), 247-258.
5. Chango, A., Boisson, F., Barbe, F., Quilliot, D., Droesch, S., Pifster, M., et al. (2000). The effect of 677CT and 1298AC mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects. British Journal of Nutrition, 83, 593-596.
6. Chinta, S. J., & Andersen, J. K. (2006). Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. Free Radical Biology and Medicine, 41, 1442-1448. (Pubitemid 44466728)
7. Condello, S., Currò, M., Ferlazzo, N., Caccamo, D., Satriano, J., &Ientile, R. (2011). Agmatine effects on mitochondrial membrane potential and NF-κB activation protect against rotenone-induced cell damage in human neuronal-like SH-SY5Y cells. Journal of Neurochemistry, 116(1), 67-75.
8. Costa, C., Belcastro, V., Tozzi, A., Di Filippo, M., Tantucci, M., Siliquini, S., et al. (2008). Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. Journal of Neuroscience, 28, 8040-8052.
9. de Lau, L. M., Koudstaal, P. J., van Meurs, J. B., Uitterlinden, A. G., Hofman, A., & Breteler, M. M. (2005). Methylenetetrahydrofolate reductase C677T genotype and PD. Annals of Neurology, 57(6), 927-930. (Pubitemid 40798634)
10. Duan, W., Ladenheim, B., Cutler, R. G., Kruman, I. I., Cadet, J. L., &Mattson, M. P. (2002). Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. Journal of Neurochemistry, 80, 101-110. (Pubitemid 34614582)
11. Fasano, M., Bergamasco, B., & Lopiano, L. (2006). Modifications of the iron-neuromelanin system in Parkinson's disease. Journal of Neurochemistry, 96, 909-916.
12. Galpern, W. R., & Cudkowicz, M. E. (2007). Coenzyme Q treatment of neurodegenerative diseases of aging. Mitochondrion, 7, S146-S153. (Pubitemid 46712231)
13. Halliday, G. M., Ophof, A., Broe, M., Jensen, P. H., Kettle, E., Fedorow, H., et al. (2005). Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain, 128, 2654-2664. (Pubitemid 41552949)
14. Hermida-Ameijeiras, A., Mendez-Alvarez, E., Sanchez-Iglesias, S., Sanmartin-Suarez, C., & Soto-Otero, R. (2004). Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: Role of ferrous and ferric ions. Neurochemistry International, 45, 103-116. (Pubitemid 38479570)
15. Hughes, A. J., Ben-Shlomo, Y., Daniel, S. E., & Lees, A. J. (1992). What features improve the accuracy of clinical diagnosis in Parkinson's disease? A clinicopathologic study. Neurology, 42, 1142-1146.
16. Isobe, C., Abe, T., & Terayama, Y. (2010). Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neuroscience Letters, 469, 159-163.
17. Jellinger, K. A. (2000). Cell death mechanisms in Parkinson's disease. Journal of Neural Transmission, 107, 1-29.
18. Lamberti, P., Zoccolella, S., Iliceto, G., Armenise, E., Fraddosio, A., de Mari, M., et al. (2005). Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Movement Disorders, 20, 69-72. (Pubitemid 40277507)
19. Mattson, M. P., & Shea, T. B. (2003). Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends in Neuroscience, 26, 137-146. (Pubitemid 36183675)
20. Obeid, R., Schadt, A., Dillmann, U., Kostopoulos, P., Fassbender, K., & Herrmann, W. (2009). Methylation status and neurodegenerative markers in Parkinson disease. Clinical Chemistry, 55(10), 1852-1860.
21. O'Suilleabhain, P. E., Oberle, R., Bartis, C., Dewey, R. B., Jr., Bottiglieri, T., & Diaz-Arrastia, R. (2006). Clinical course in Parkinson's disease with elevated homocysteine. Parkinsonism Related Disorders, 12(2), 103-107. (Pubitemid 43234311)
22. O'Suilleabhain, P. E., Sung, V., Hernandez, C., Lacritz, L., Dewey, R. B., Jr., Bottiglieri, T., et al. (2004). Elevated plasma homocysteine level in patients with Parkinson disease: Motor, affective, and cognitive associations. Archives of Neurology, 61, 865-868. (Pubitemid 38747325)
23. Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., et al. (2004). Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. Journal of Biological Chemistry, 279, 18614-18622. (Pubitemid 38623283)
24. Postuma, R. B., & Lang, A. E. (2004). Homocysteine and levodopa. Should Parkinson disease patients receive preventative therapy? Neurology, 63, 886-891. (Pubitemid 39297652)
25. Prigione, A., Begni, B., Galbussera, A., Beretta, S., Brighina, L., Garofalo, R., et al. (2006). Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage. Neurobiological Disease, 23(1), 36-43. (Pubitemid 43903629)
26. Rajabally, Y. A., & Martey, J. (2011). Neuropathy in Parkinson disease: Prevalence and determinants. Neurology, 77(22), 1947-1950.
27. Schneider, J. A., Rees, D. C., Liu, Y. T., & Clegg, J. B. (1998). Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. American Journal of Human Genetics, 62(5), 1258-1260. (Pubitemid 28199029)
28. Shults, C. W., Haas, R. H., Passov, D., & Beal, M. F. (1997). Coenzyme Q10 levels correlate with the activities of the complex I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Annals of Neurology, 42, 261-264. (Pubitemid 27340475)
29. Shults, C. W., Oakes, D., Kieburtz, K., et al. (2002). Effects of coenzyme Q-sub-1-sub-0 in early Parkinson disease: Evidence of slowing of the functional decline. Arch Neurology, 59, 1541-1550.
30. Sohmiya, M., Tanaka, M., Tak, N. W., Yanagisawa, M., Tanino, Y., Suzuki, Y., et al. (2004). Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease. Journal of Neurological Sciences, 223, 161-166. (Pubitemid 39164358)
31. Stephans, S. E., Miller, G. W., Levey, A. I., & Greenamyre, J. T. (2002). Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells. Neurotoxicology, 23(4-5), 569-580. (Pubitemid 36527677)
32. Storch, A., Jost, W. H., Vieregge, P., et al. (2007). (2007) Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease. Arch Neurology, 64(7), 938-944. (Pubitemid 47047992)
33. Todorovic, Z., Dzoljic, E., Novakovic, I., Mirković, D., Stojanović, R., Nesić, Z., et al. (2006). Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. Journal of Neurological Sciences, 248, 56-61. (Pubitemid 44647314)
34. Yamashita, S., & Yamamoto, Y. (1997). Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. Analytical Biochemistry, 250, 66-73. (Pubitemid 27310315)
35. Yasuda, T., Hayakawa, H., Nihira, T., Ren, Y. R., Nakata, Y., Nagai, M., et al. (2011). Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of Parkinson disease. Journal of Neuropathology and Experimental Neurology, 70(8), 686-697.
36. Yasui, K., Kowa, H., Nakaso, K., Takeshima, T., & Nakashima, K. (2000). Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology, 55, 437-440. (Pubitemid 30650089)
37. Young, A. J., Johnson, S., Steffens, D. C., & Doraiswamy, P. M. (2007, Jan). Coenzyme Q10: A review of its promise as a neuroprotectant. CNS Spectr, 12(1), 62-68. (Pubitemid 46155305)
38. Zoccolella, S., dell'Aquila, C., Abruzzese, G., Antonini, A., Bonuccelli, U., Canesi, M., et al. (2009). Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. Movement Disorders, 24(7), 1028-1033.
39. Zou, C. G., & Banerjee, R. (2005). Homocysteine and redox signaling. Antioxidants & Redox Signaling, 7, 547-559.